MEDROXYPROGESTERONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H32O3
Molecular Weight	344.4877
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)CC[C@]34C

InChI

InChIKey=FRQMUZJSZHZSGN-HBNHAYAOSA-N

InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf

Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. Medroxyprogesterone acetate (MPA) administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered MPA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Progesterone receptor 61 Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8852830	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Secondary amenorrhea 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf	Primary	Approved 8429	PROVERA Approved Use Medroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Launch Date 1959
Abnormal uterine bleeding 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf	Primary	Approved 8429	PROVERA Approved Use Medroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Launch Date 1959
Endometrial cancer 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf	Preventing	Approved 8429	PROVERA Approved Use Medroxyprogesterone Acetate Tablets USP are a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone Acetate Tablets USP are also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. Launch Date 1959

C_max

Value	Dose	Co-administered	Analyte	Population
0.71 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEDROXYPROGESTERONE ACETATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6.01 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEDROXYPROGESTERONE ACETATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
16.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEDROXYPROGESTERONE ACETATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEDROXYPROGESTERONE ACETATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

Doses

Dose	Population	Adverse events
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf Page: p.7	healthy, 15 - 51 n = 3900 Health Status: healthy Condition: Prevention of pregnancy Age Group: 15 - 51 Sex: F Population Size: 3900 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf Page: p.7	Disc. AE: Bleeding, Amenorrhea... AEs leading to discontinuation/dose reduction: Bleeding (8.2%) Amenorrhea (2.1%) Weight gain (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf Page: p.7
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: E2V, p.o(2 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/15107205 Page: p.12	healthy, 45-66 n = 132 Health Status: healthy Condition: Postmenopause Age Group: 45-66 Sex: F Population Size: 132 Sources: https://pubmed.ncbi.nlm.nih.gov/15107205 Page: p.12	Disc. AE: Bleeding, Uterine fibroids... AEs leading to discontinuation/dose reduction: Bleeding (3.8%) Uterine fibroids (2.3%) Gallstones (0.76%) Endometrial polyp (0.76%) Sources: https://pubmed.ncbi.nlm.nih.gov/15107205 Page: p.12
2.5 mg 1 times / day multiple, oral Studied dose Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: https://pubmed.ncbi.nlm.nih.gov/16875644 Page: p.1325	healthy, 45-79 n = 284 Health Status: healthy Condition: Postmenopause Age Group: 45-79 Sex: F Population Size: 284 Sources: https://pubmed.ncbi.nlm.nih.gov/16875644 Page: p.1325	Disc. AE: Bleeding vaginal... AEs leading to discontinuation/dose reduction: Bleeding vaginal (9%) Sources: https://pubmed.ncbi.nlm.nih.gov/16875644 Page: p.1325
10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1, p.5	healthy, 50 -79 n = 8506 Health Status: healthy Condition: Postmenopause Age Group: 50 -79 Sex: F Population Size: 8506 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1, p.5	Disc. AE: Myocardial infarction, Stroke... AEs leading to discontinuation/dose reduction: Myocardial infarction Stroke Breast cancer invasive NOS Embolism pulmonary Deep vein thrombosis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1, p.5
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20733445/ Page: p.628	unhealthy, >18 n = 83 Health Status: unhealthy Condition: Idiopathic heavy menstrual bleeding Age Group: >18 Sex: F Population Size: 83 Sources: https://pubmed.ncbi.nlm.nih.gov/20733445/ Page: p.628	Disc. AE: Dizziness, Fluid retention... AEs leading to discontinuation/dose reduction: Dizziness (1.2%) Fluid retention (1.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/20733445/ Page: p.628
2.5 mg 1 times / day multiple, oral Studied dose Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Co-administed with:: conjugated estrogens, p.o(0.625 mg; q.d) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1, p.5	healthy, >65 Health Status: healthy Condition: Postmenopause Age Group: >65 Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1, p.5	Disc. AE: Dementia... AEs leading to discontinuation/dose reduction: Dementia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1, p.5
10 mg 1 times / day multiple, oral (max) Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Secondary Amenorrhea\|Abnormal Uterine Bleeding Due to Hormonal Imbalance Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1	Disc. AE: Cardiovascular disorder... AEs leading to discontinuation/dose reduction: Cardiovascular disorder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf Page: p.1
150 mg 3 times / month multiple, intramuscular Recommended Dose: 150 mg, 3 times / month Route: intramuscular Route: multiple Dose: 150 mg, 3 times / month Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf Page: p.1	healthy Health Status: healthy Condition: Prevention of pregnancy Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf Page: p.1	Disc. AE: Bone density abnormal... AEs leading to discontinuation/dose reduction: Bone density abnormal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C8 911	CYP1A1 349 CYP1A2 1054 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2C19 991 CYP2E1 667 CYP3A5 395

Drug as perpetrator

Target	Modality	Activity
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	moderate [IC50 16.1 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	slight [IC50 >100 uM]
CYP2A6 739	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	slight [IC50 >100 uM]
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	slight [IC50 >100 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	slight [IC50 >100 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	weak [IC50 31.5 uM]
CYP2E1 970	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/16645869/	yes
CYP3A4 1925	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/11301566/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 349	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP1A2 1054	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2A6 543	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2B6 664	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2C18 138	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2C19 991	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2C8 693	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2C9 1037	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2D6 1217	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP2E1 667	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297	no
CYP3A5 395	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297; https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf#page=1	no
CYP3A4 1737	substrate 3367 Sources: https://clincancerres.aacrjournals.org/content/6/8/3297; https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf#page=1	yes	likely (co-administration study) Comment: Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of contraceptive drug products. Sources: https://clincancerres.aacrjournals.org/content/6/8/3297; https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf#page=1

PubMed

Title	Date	PubMed
Autophagy and nuclear changes in FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro.	2001	11872957
Organ preserving method in the management of atypical endometrial hyperplasia.	2001	11695813
Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep.	2001 Dec	11829107
A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.	2001 Dec	11794823
[Results of treatment based on endocrine therapy for bone metastasis from breast cancer].	2001 Dec	11791380
An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy.	2001 Dec	11788110
Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas.	2001 Dec	11755553
Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors.	2001 Dec	11755552
Hormone replacement therapy and endothelial function: the exception that proves the rule?	2001 Dec	11742856
Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women.	2001 Dec	11730815
Current options for injectable contraception in the United States.	2001 Dec	11727175
Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women.	2001 Dec	11701433
How to use progestin in hormone replacement therapy: an animal experiment.	2001 Feb	11780201
Monthly injection provides new contraceptive choice.	2001 Jan-Feb	11930928
Quinacrine non-surgical female sterilization in Bangladesh.	2001 Nov	11777487
A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys.	2001 Nov	11701713
The influence of apo E phenotypes on the plasma triglycerides response to hormonal replacement therapy during the menopause.	2001 Nov 30	11716996
New options in contraception for adolescents.	2001 Oct	12112958
Anaylsis of birefringence during wound healing and remodeling following alkali burns in rabbit cornea.	2001 Oct	11825023
[Clinical analysis of pulmonary lymphangioleiomyomatosis].	2001 Oct 25	11825531
Interactions between antiepileptic drugs and hormonal contraception.	2002	11945109
Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels.	2002	11803230
Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report.	2002 Apr	11925144
Contraceptive efficacy and patient acceptance of Lunelle.	2002 Aug	12242850
Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women.	2002 Aug	12197367
Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis.	2002 Aug	12181616
Effect of methyl testosterone administration on plasma viscosity in postmenopausal women.	2002 Aug	12153599
High-risk teen compliance with prescription contraception: an analysis of Ohio Medicaid claims.	2002 Feb	11888805
Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.	2002 Feb	11888095
[A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].	2002 Feb	11865641
Effects of hormonal replacement therapy on oxidative stress and total antioxidant capacity in postmenopausal hemodialysis patients.	2002 Jan	11921698
Estrogen therapy for unstable angina: another bump for the bandwagon.	2002 Jan 16	11788213
Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina.	2002 Jan 16	11788212
HRT: forever or never?	2002 Jul-Aug	12199410
Medroxyprogesterone-induced endocrine alterations after menopause.	2002 Jul-Aug	12082365
Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women.	2002 Jul-Aug	12082361
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study.	2002 Jun	12123333
New developments in contraception.	2002 Jun	12106759
Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women.	2002 Mar	11889163
Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women.	2002 Mar	11872199
Pharmacological characterization of the ATP-dependent low K(m) guanosine 3',5'-cyclic monophosphate (cGMP) transporter in human erythrocytes.	2002 Mar 1	11911846
Effect of postmenopausal hormone therapy on cardiovascular risk.	2002 May	12183856
[Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].	2002 May	12133397
Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.	2002 May	12015523
Effect of medroxyprogesterone on pulmonary arterial pressure, exhaled nitric oxide, ECG and arterial blood gases.	2002 May	11982742
[Positive effects of estrogens on cardiovascular health].	2002 May 2	12082786
Contraceptive applications of estrogen.	2002 May-Jun	12071380
Influence of estradiol and gestagens on oxidative stress in the rat uterus.	2002 Sep	12217744
Chronic respiratory failure: an unusual cause and treatment.	2002 Sep	12200531
Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study.	2002 Sep 30	12270580

Patents

Sample Use Guides

In Vivo Use Guide

Secondary Amenorrhea: PROVERA (medroxyprogesterone acetate ) tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days. Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of Organic Pathology: Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of PROVERA may be given daily for 5 to 10 days. Reduction of Endometrial Hyperplasia in Postmenopausal Women: Receiving Daily 0.625 mg Conjugated Estrogens

Route of Administration: Oral

In Vitro Use Guide

Freshly isolated PBMCs (peripheral blood mononuclear cells) from normal blood donors were treated with physiologic MPA (medroxyprogesterone acetate) concentrations ranging from 0.003 to 5 ng/ml and infected with GFP-tagged R5-tropic or X4-tropic HIV-1 pseudoviruses by spinoculation. The infection was limited to a single cycle. Cells were stained with CD3, CD8 and CD14

Name

Type

Language

MEDROXYPROGESTERONE

Official Name

English

MEDROXYPROGESTERONE [VANDF]

Common Name

English

Medroxyprogesterone [WHO-DD]

Common Name

English

MEDROXYPROGESTERONE ACETATE IMPURITY B [WHO-IP]

Common Name

English

MEDROXYPROGESTERONE [WHO-IP]

Common Name

English

NSC-27408

Code

English

medroxyprogesterone [INN]

Common Name

English

MEDROXYPROGESTERONE [MI]

Common Name

English

17-HYDROXY-6.ALPHA.-METHYLPREGN-4-ENE-3,20-DIONE

Systematic Name

English

MEDROXYPROGESTERONE ACETATE RELATED COMPOUND B [USP-RS]

Common Name

English

G03AC06

Code

English

MEDROXYPROGESTERONE ACETATE IMPURITY B [EP IMPURITY]

Common Name

English

MEDROXYPROGESTERONE [HSDB]

Common Name

English

MEDROXYPROGESTERONE ACETATE RELATED COMPOUND B

Common Name

English

FARLUTAL INYECTABLE

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C776